title: Micafungin concentrations in the plasma and burn eschar of severely burned patients.
abstract: Micafungin concentrations in plasma and burn eschar after daily intravenous infusion (1 h) of micafungin (200 to 300 mg) were investigated for six patients with severe burns. Micafungin treatment was initiated more than 72 h after the burn injuries. The peak and trough levels in the plasma after the initial administration and repeated administrations for more than 4 days were comparable with or slightly lower than the reported values for healthy volunteers. Micafungin concentrations in the plasma and burn eschar were between 3.6 and >1,000 times higher than the reported MIC(90)s of micafungin against clinically important Candida and Aspergillus species.
authors.affiliation: Department of Emergency and Critical Care Medicine, School of Medicine, Keio University, Tokyo, Japan. sasakij@1989.jukuin.keio.ac.jp
authors.forename: Junichi
authors.initials: J
authors.lastname: Sasaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamanouchi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kudo
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Endo
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Nomura
authors.forename: Kiyotsugu
authors.initials: K
authors.lastname: Takuma
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kushimoto
authors.forename: Yotaro
authors.initials: Y
authors.lastname: Shinozawa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kishino
authors.forename: Shingo
authors.initials: S
authors.lastname: Hori
authors.forename: Naoki
authors.initials: N
authors.lastname: Aikawa
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics*; D002056:Burns / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D054714:Echinocandins / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D055666:Lipopeptides / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics*; D008297:Male; D000077551:Micafungin; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077551:Micafungin
references.citation: Drug Metab Pharmacokinet. 2006 Aug;21(4):324-31
references.pmid: 16946560
references.citation: Burns. 2011 Mar;37(2):181-95
references.pmid: 20395056
references.citation: Clin Pharmacokinet. 2008;47(10):635-54
references.pmid: 18783295
references.citation: J Antimicrob Chemother. 1999 Sep;44(3):319-27
references.pmid: 10511398
references.citation: Drugs. 2004;64(9):969-82; discussion 983-4
references.pmid: 15101786
references.citation: Clin Pharmacokinet. 1995 Jul;29(1):15-28
references.pmid: 7586895
references.citation: Clin Pharmacokinet. 2005;44(10):1009-34
references.pmid: 16176116
references.citation: Eur J Drug Metab Pharmacokinet. 2008 Jul-Sep;33(3):191-8
references.pmid: 19007046
references.citation: Biol Pharm Bull. 2004 Jul;27(7):1154-6
references.pmid: 15256761
references.citation: J Clin Pharmacol. 2005 Oct;45(10):1145-52
references.pmid: 16172179
references.citation: Antimicrob Agents Chemother. 1998 Apr;42(4):930-3
references.pmid: 9559811
references.citation: J Infect Chemother. 2009 Aug;15(4):219-27
references.pmid: 19688240
references.citation: Clinics (Sao Paulo). 2010 Feb;65(2):237-43
references.pmid: 20186309
references.citation: J Burn Care Res. 2010 Mar-Apr;31(2):257-63
references.pmid: 20182372